Matthew Korenberg

2020

In 2020, Matthew Korenberg earned a total compensation of $3.1M as Executive Vice President, Finance and Chief Financial Officer at Ligand Pharmaceuticals, a 13% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$265,558
Option Awards$1,206,821
Salary$482,833
Stock Awards$1,150,224
Other$5,700
Total$3,111,136

Korenberg received $1.2M in option awards, accounting for 39% of the total pay in 2020.

Korenberg also received $265.6K in non-equity incentive plan, $482.8K in salary, $1.2M in stock awards and $5.7K in other compensation.

Rankings

In 2020, Matthew Korenberg's compensation ranked 3,735th out of 13,090 executives tracked by ExecPay. In other words, Korenberg earned more than 71.5% of executives.

ClassificationRankingPercentile
All
3,735
out of 13,090
72nd
Division
Manufacturing
1,477
out of 5,618
74th
Major group
Chemicals And Allied Products
556
out of 2,251
75th
Industry group
Drugs
482
out of 1,951
75th
Industry
Pharmaceutical Preparations
363
out of 1,456
75th
Source: SEC filing on April 22, 2022.

Korenberg's colleagues

We found three more compensation records of executives who worked with Matthew Korenberg at Ligand Pharmaceuticals in 2020.

2020

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2020

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2020

Charles Berkman

Ligand Pharmaceuticals

General Counsel

News

You may also like